home / stock / ikt / ikt news

IKT News and Press, Inhibikase Therapeutics Inc.

Stock Information
Company Name: Inhibikase Therapeutics Inc.
Stock Symbol: IKT
Market: NASDAQ
Website: inhibikase.com
Menu
IKT IKT Quote IKT Short IKT News IKT Articles IKT Message Board
Get IKT Alerts

News, Short Squeeze, Breakout and More Instantly...
IKT - Inhibikase Therapeutics files to sell 4.76M shares of common stock for holders

2024-06-18 17:44:20 ET More on Inhibikase Therapeutics Inhibikase Therapeutics prices its direct offering, warrant inducement Seeking Alpha’s Quant Rating on Inhibikase Therapeutics Historical earnings data for Inhibikase Therapeutics Read the full a...
IKT - Inhibikase Therapeutics Completes Enrollment of the Phase 2 '201' Trial Evaluating Risvodetinib in Untreated Parkinson's Disease

BOSTON and ATLANTA, June 17, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinso...

IKT - Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs

- Company positioning multiple assets for late-stage development across its therapeutic pipeline – BOSTON and ATLANTA, June 05, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kin...

IKT - Inhibikase Therapeutics prices its direct offering, warrant inducement

2024-05-20 08:12:14 ET More on Inhibikase Therapeutics Seeking Alpha’s Quant Rating on Inhibikase Therapeutics Historical earnings data for Inhibikase Therapeutics Financial information for Inhibikase Therapeutics Read the full article on Seeking Alp...
IKT - Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million

BOSTON and ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson...

IKT - Inhibikase Therapeutics, Inc. (IKT) Q1 2024 Earnings Call Transcript

2024-05-17 21:57:08 ET Inhibikase Therapeutics, Inc. (IKT) Q1 2024 Earnings Conference Call May 16, 2024 08:00 AM ET Company Participants Alexander Lobo - Stern Investor Relations Milton Werner - CEO Garth Lees-Rolfe - CFO Conference Call Participants ...

IKT - Inhibikase Therapeutics GAAP EPS of -$0.73

2024-05-16 12:22:51 ET More on Inhibikase Therapeutics Seeking Alpha’s Quant Rating on Inhibikase Therapeutics Historical earnings data for Inhibikase Therapeutics Financial information for Inhibikase Therapeutics Read the full article on Seeking Alp...
IKT - GoodRx Holdings, Seelos Therapeutics, Clever Leaves among healthcare movers

2024-05-16 10:00:47 ET More on Health Care Select Sector SPDR XLV: Healthcare Is Ripe For Buying, Despite Patent Cliff XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care Short interest in S&P 500 ...

IKT - Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement

BOSTON and ATLANTA, May 15, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson...

IKT - Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension

- FDA indicated IkT-001Pro can be considered a New Molecular Entity and is eligible for exclusivity designations in Pulmonary Arterial Hypertension – BOSTON and ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or &#...
Next 10